BuSpar Antitrust Suit Will Test Theory Of “Orange Book” Abuse
Executive Summary
A multi-state antitrust suit against Bristol-Myers Squibb over the BuSpar patent challenge will test the theory that some manufacturers are abusing the "Orange Book" patent listing process
You may also be interested in...
Bristol Will Not Ask FDA To Relist BuSpar Patent If Mylan Wins Patent Case
Bristol-Myers Squibb will not ask FDA to relist its November 2000 BuSpar patent in the "Orange Book" if Mylan wins its challenge of the patent's validity in Manhattan federal court
Bristol Will Not Ask FDA To Relist BuSpar Patent If Mylan Wins Patent Case
Bristol-Myers Squibb will not ask FDA to relist its November 2000 BuSpar patent in the "Orange Book" if Mylan wins its challenge of the patent's validity in Manhattan federal court
“Orange Book” Listings Are Not Immune From Antitrust Scrutiny, FTC Says
"Orange Book" patent listings should not be afforded the same antitrust exemption given to "petitioning," the Federal Trade Commission maintains in an amicus curiae brief filed as part of a state attorneys general action against Bristol-Myers Squibb